-
公开(公告)号：WO2020158958A1
公开(公告)日：2020-08-06
申请号：PCT/JP2020/004444
申请日：2020-01-30
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： HATTORI, Yasushi , MIYANOHANA, Yuhei , KAJITA, Yuichi , KOIKE, Tatsuki , HOASHI, Yasutaka , TOKUNAGA, Norihito , PAWLICZEK, Alexander Martin , ODA, Tsuneo , MIYAZAKI, Tohru , ITO, Yoshiteru , TAKEUCHI, Kohei , IMAMURA, Keisuke , SUGIMOTO, Takahiro
IPC: A61P3/00 , A61K31/40 , A61K31/4025 , A61K31/422 , A61K31/427 , A61K31/4439 , C07D207/14 , C07D401/10 , C07D403/10 , C07D403/14 , C07D407/06 , C07D413/10 , C07D417/10
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
-
2.发明申请2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR 审中-公开作为胆碱受体M1受体的调节剂的2,3-二氢-4H-1,3-苯并恶嗪-4-酮衍生物
公开(公告)号：WO2016208775A1
公开(公告)日：2016-12-29
申请号：PCT/JP2016/069189
申请日：2016-06-23
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： SUGIMOTO, Takahiro , SUZUKI, Shinkichi , SAKAMOTO, Hiroki , YAMADA, Masami , NAKAMURA, Minoru , KAMATA, Makoto , SHIMOKAWA, Kenichiro , OGINO, Masaki , KIMURA, Eiji , MURAKAMI, Masataka , YONEMORI, Jinichi , KOJIMA, Takuto
IPC: C07D413/14 , C07D413/10 , C07D413/06 , C07D413/04 , C07D417/06 , C07D265/22 , C07D471/04 , C07D491/107 , A61P25/00 , A61K31/536 , A61K31/541 , A61P29/00
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
Abstract translation: 本发明提供具有胆碱能毒蕈碱M1受体正变构调节剂活性的化合物，其可用作阿尔茨海默氏病，精神分裂症，疼痛，睡眠障碍，帕金森病痴呆，路易体痴呆等的预防或治疗药物。 本发明涉及由式（I）表示的化合物或其盐：其中每个符号如所附的说明中所定义。
-
3.发明申请ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE 审中-公开ISOINDOLINE-1-ONE衍生物作为胆碱性MUSCARINIC M1受体阳性氧化酶调节剂活性治疗阿尔茨海默病
公开(公告)号：WO2015163485A1
公开(公告)日：2015-10-29
申请号：PCT/JP2015/062912
申请日：2015-04-22
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： YAMADA, Masami , SUZUKI, Shinkichi , SUGIMOTO, Takahiro , NAKAMURA, Minoru , SAKAMOTO, Hiroki , KAMATA, Makoto
IPC: C07D209/46 , A61K31/435 , A61P29/00
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. (I) wherein each symbol is as described in the specification, or a salt thereof.
Abstract translation: 本发明提供了具有胆碱能毒蕈碱M1受体阳性变构调节剂活性的化合物，可用作预防或治疗阿尔茨海默病，精神分裂症，疼痛，睡眠障碍，帕金森病痴呆，路易体痴呆等。 本发明涉及由式（I）表示的化合物或其盐。 （I）其中每个符号如说明书中所述，或其盐。
-
4.发明授权
公开(公告)号：EP3313836B1
公开(公告)日：2020-11-11
申请号：EP16756814.6
申请日：2016-06-23
Applicant: Takeda Pharmaceutical Company Limited
Inventor： SUGIMOTO, Takahiro , SUZUKI, Shinkichi , SAKAMOTO, Hiroki , YAMADA, Masami , NAKAMURA, Minoru , KAMATA, Makoto , SHIMOKAWA, Kenichiro , OGINO, Masaki , KIMURA, Eiji , MURAKAMI, Masataka , YONEMORI, Jinichi , KOJIMA, Takuto
IPC: C07D413/14 , C07D413/10 , C07D413/06 , C07D413/04 , C07D417/06 , C07D265/22 , C07D471/04 , C07D491/107 , A61P25/00 , A61K31/536 , A61K31/541 , A61P29/00
-
公开(公告)号：EP2821401B1
公开(公告)日：2020-09-09
申请号：EP13754154.6
申请日：2013-02-28
Applicant: Takeda Pharmaceutical Company Limited
Inventor： SAKAMOTO, Hiroki , SUGIMOTO, Takahiro
IPC: C07D215/56 , A61K31/47 , A61K31/4709 , A61K31/502 , A61K31/5377 , A61P25/04 , A61P25/18 , A61P25/20 , A61P25/28 , A61P43/00 , C07D237/28 , C07D401/10 , C07D401/12 , C07D405/12
-
Patent Agency Ranking
公开(公告)号：EP3287454A1
公开(公告)日：2018-02-28
申请号：EP16783269.0
申请日：2016-04-22
Applicant: Takeda Pharmaceutical Company Limited
Inventor： KAMEI, Taku , ARIKAWA, Yasuyoshi , OHASHI, Tomohiro , IMAEDA, Toshihiro , FUJIMORI, Ikuo , MIKI, Takashi , YONEMORI, Jinichi , OGURO, Yuya , SUGIMOTO, Takahiro , SETO, Masaki , NISHIDA, Goushi , KAMATA, Makoto , IMOTO, Hiroshi
IPC: C07D413/14 , A61K31/553 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P43/00 , C07D413/04 , C07D417/14
Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as defined in the specification, or a salt thereof.Abstract translation: 本发明提供具有食欲素受体拮抗作用的化合物，其预期可用作药物，例如用于预防或治疗睡眠障碍，抑郁症，焦虑症，恐慌症，精神分裂症，药物依赖，阿尔茨海默氏病和 喜欢。 本发明涉及由式（I）表示的化合物或其盐，其中每个符号如说明书中所定义。
-
7.发明公开ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE 审中-公开异吲哚，与胆碱能毒蕈碱M1受体阳性ALLOESTERISCHER调节剂活性的用于治疗阿尔茨海默氏病的衍生物
公开(公告)号：EP3134386A1
公开(公告)日：2017-03-01
申请号：EP15726362.5
申请日：2015-04-22
Applicant: Takeda Pharmaceutical Company Limited
Inventor： YAMADA, Masami , SUZUKI, Shinkichi , SUGIMOTO, Takahiro , NAKAMURA, Minoru , SAKAMOTO, Hiroki , KAMATA, Makoto
IPC: C07D209/46 , A61K31/435 , A61P29/00
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
Abstract translation: worin每个符号如说明书中所描述的，或它们的盐。
-
公开(公告)号：EP4046688A1
公开(公告)日：2022-08-24
申请号：EP20877776.3
申请日：2020-10-15
Applicant: Takeda Pharmaceutical Company Limited
Inventor： TOYOFUKU, Masashi , ITO, Yoshiteru , PIRA, Marilena , SUGIMOTO, Takahiro
IPC: A61P25/02 , C07D405/12 , C07D487/04 , C07D498/04 , C07D231/56 , A61K31/416 , A61K31/437 , A61K31/5365
Abstract: The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof.-
公开(公告)号：EP3816153A1
公开(公告)日：2021-05-05
申请号：EP19825506.9
申请日：2019-06-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： ODA, Tsuneo , ITO, Yoshiteru , MIYAZAKI, Tohru , TAKEUCHI, Kohei , TOKUNAGA, Norihito , HOASHI, Yasutaka , HATTORI, Yasushi , IMAMURA, Keisuke , KAJITA, Yuichi , MIYANOHANA, Yuhei , SUGIMOTO, Takahiro , KOIKE, Tatsuki , UYGHUR, Dilhumar
IPC: C07D207/14 , A61K31/40 , A61K31/426 , A61K31/4439 , A61K31/445 , A61P25/18 , A61P25/26 , C07D211/56 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D417/14
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
10.发明公开2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR 审中-公开2,3-二氢-4H-1,3-苯并恶嗪-4-酮衍生物作为胆碱能受体M1受体调节剂
公开(公告)号：EP3313836A1
公开(公告)日：2018-05-02
申请号：EP16756814.6
申请日：2016-06-23
Applicant: Takeda Pharmaceutical Company Limited
Inventor： SUGIMOTO, Takahiro , SUZUKI, Shinkichi , SAKAMOTO, Hiroki , YAMADA, Masami , NAKAMURA, Minoru , KAMATA, Makoto , SHIMOKAWA, Kenichiro , OGINO, Masaki , KIMURA, Eiji , MURAKAMI, Masataka , YONEMORI, Jinichi , KOJIMA, Takuto
IPC: C07D413/14 , C07D413/10 , C07D413/06 , C07D413/04 , C07D417/06 , C07D265/22 , C07D471/04 , C07D491/107 , A61P25/00 , A61K31/536 , A61K31/541 , A61P29/00
Abstract: wherein each symbol is as defined in the attached DESCRIPTION.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.038 seconds)
